PRESS RELEASE FROM NATURE BIOTECHNOLOGY
http://www.nature.com/naturebiotechnology
For papers that will be published on 30 November 2007
This press release is copyrighted to Nature Biotechnology.
PLEASE CITE Nature BIOTECHNOLOGY AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO THE JOURNAL’S WEBSITE, http://www.nature.com/naturebiotechnology
Editorial contacts: While the best contacts for stories will always be the authors themselves, in some cases the Nature editor who handled the paper will be available for comment if an author is unobtainable. Editors are contactable via Ruth Francis on +44 20 7843 4562. Feel free to get in touch with Nature's press contacts in London, Washington and Tokyo (as listed at the end of this release) with any general editorial inquiry.
PICTURES: While we are happy for images from Nature to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).
HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at [email protected], citing the specific example.
Induced pluripotent stem cells without tumours
DOI: 10.1038/nbt1374
Building on their research reported last week, Shinya Yamanaka and colleagues show how to convert adult mouse or human skin cells into cells that resemble embryonic stem cells without using the tumour-causing gene c-Myc. The paper will be published online in Nature Biotechnology. Elimination of c-Myc is considered a critical step in making these so-called ‘reprogrammed’ cells safe for clinical applications in patients.
As originally described, the reprogramming method works by introducing four specific genes into skin cells and identifying the rare cells, known as induced pluripotent stem (iPS) cells, that acquire properties of pluripotency – the ability to become any specialized cell of the body. The method was demonstrated by Yamanaka’s group in publications in 2006 and 2007 using cells from mice. Last week, two papers reported success with human cells. However, one of these papers – also from Yamanaka’s group – used the c-Myc gene, which makes iPS cells prone to form tumours, and the other one – from a US team – used fetal and neonatal cells rather than adult cells.
The authors demonstrate the generation of iPS cells from adult mouse and human skin cells with only three genes, not including c-Myc. To determine whether the absence of c-Myc reduces the propensity to form tumours, the authors studied mouse iPS cells in a rigorous test that involves generating ‘chimeric’ mice harbouring many specialized cells derived from the iPS cells. None of the 26 animals derived from iPS cells without c-Myc died of tumours (at the last, 100-day time point), whereas 6 of 37 animals from iPS cells with c-Myc did, showing that the absence of c-Myc reduces tumour incidence.
The human skin cells reprogrammed in the present study came from a 36-year-old adult. Reprogramming adult cells may be more clinically relevant than reprogramming neonatal cells as in principle it would make patient-specific pluripotent cells available to adults for use in cell-replacement therapies.
Author contact:
Shinya Yamanaka (Kyoto University, Japan)
Tel: +81 75 751 4864; [email protected]
Editorial contact:
Peter Hare (Nature Biotechnology, New York)
Tel: +1 212 726 9284; E-mail: [email protected]
Press contacts:
Katherine Anderson (Nature London)
Tel: +44 20 7843 4502; E-mail: [email protected]
Ruth Francis (Senior Press Officer, Nature, London)
Tel: +44 20 7843 4562; E-mail: [email protected]
About Nature Publishing Group
Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through [email protected] and scientific career information through Naturejobs.
NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to www.nature.com.
